{"doi":"10.1038/npp.2009.39","title":"A Haplotype of the Norepinephrine Transporter (Net) Gene Slc6a2 is Associated with Clinical Response to Atomoxetine in Attention-Deficit Hyperactivity Disorder (ADHD)","abstract":null,"journal":"Neuropsychopharmacology","year":2009,"id":619523,"datarank":0.6141516843333151,"base_score":4.0943445622221,"endowment":4.0943445622221,"self_citation_contribution":0.6141516843333151,"citation_network_contribution":0.0,"self_endowment_contribution":0.6141516843333151,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":59,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":306295,"name":"Claudette Boni","orcid":null,"position":1,"is_corresponding":false},{"id":1598809,"name":"AnnCatherine M Downing","orcid":null,"position":2,"is_corresponding":false},{"id":1598810,"name":"Sandra L Close","orcid":null,"position":3,"is_corresponding":false},{"id":1598811,"name":"Sandra L Peters","orcid":null,"position":4,"is_corresponding":false},{"id":1598812,"name":"Angela M Prokop","orcid":null,"position":5,"is_corresponding":false},{"id":1514931,"name":"Albert J Allen","orcid":null,"position":6,"is_corresponding":false},{"id":172246,"name":"Michel Hamon","orcid":null,"position":7,"is_corresponding":false},{"id":1420519,"name":"Diane Purper-Ouakil","orcid":null,"position":8,"is_corresponding":false},{"id":304159,"name":"Philip Gorwood","orcid":"0000-0003-1845-3676","position":9,"is_corresponding":false},{"id":622423,"name":"Nicolas Ramoz","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A Haplotype of the Norepinephrine Transporter (Net) Gene Slc6a2 is Associated with Clinical Response to Atomoxetine in Attention-Deficit Hyperactivity Disorder (ADHD)","abstract":"Atomoxetine is a specific inhibitor of the norepinephrine transporter (NET) that has demonstrated efficacy in the treatment of children with attention-deficit hyperactivity disorder (ADHD). We investigated whether polymorphisms in the NET/SLC6A2 gene may influence atomoxetine response in ADHD. Two independent cohorts of 160 and 105 ADHD children treated for 6 weeks with atomoxetine (0.5-1.8 mg/kg per day) were genotyped on CYP2D6, which metabolizes atomoxetine, and 108 single nucleotide polymorphisms in the NET/SLC6A2 gene. Response was defined as a minimum decrease of 25% in ADHD Rating Scale IV-Parent Version and a Clinical Global Impression-Severity (CGI-S) score less than or equal to 2 at week 6. Interindividual response was independent of the genetic variants of CYP2D6. Significant (p<0.05) associations between 20 NET/SLC6A2 single nucleotide polymorphisms (SNPs) and clinical efficacy in atomoxetine responders, compared with non-responders, were observed. The genomic region across exons 4 to 9 of NET/SLC6A2, where 36 SNPs have been genotyped, was associated with treatment response in both cohorts (p<0.01, odds ratio=2.2 and p=0.026, odds ratio=6.3, respectively), in the combined cohort (p<0.01, odds ratio=1.83), and in the subgroup of Caucasians only (p=0.02, odds ratio=1.8). Clinical efficacy of atomoxetine treatment in ADHD shows potential dependence upon a series of genetic polymorphisms of its mechanistic target, the norepinephrine transporter. Taking into account the high heritability of ADHD, the significance of the present finding and replication of a similar haplotype allele sequence result in an independent cohort, it is suggested that further assessment of this region could be useful in determining response to atomoxetine in ADHD.","is_dataset_classified":null,"base_score":4.0943445622221,"endowment":4.0943445622221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19387424","pmcid":null,"openalex_id":"https://openalex.org/W2120036296","authors":[],"funders":[],"total_grants":0,"fwci":2.9406,"citation_percentile":0.90637049,"influential_citations":0,"citation_trend":[{"year":2012,"count":6},{"year":2013,"count":3},{"year":2014,"count":5},{"year":2015,"count":3},{"year":2016,"count":5},{"year":2019,"count":3},{"year":2020,"count":1},{"year":2021,"count":4},{"year":2022,"count":5},{"year":2023,"count":4},{"year":2024,"count":4},{"year":2025,"count":1},{"year":2026,"count":3}],"oa_status":"bronze","license":"http://www.springer.com/tdm","oa_locations":[{"url":"https://www.nature.com/articles/npp200939.pdf","host_type":"journal"},{"url":"https://www.nature.com/articles/npp200939.pdf","host_type":"publisher"},{"url":"http://www.nature.com/articles/npp200939.pdf","host_type":"publisher"},{"url":"http://www.nature.com/articles/npp200939","host_type":"publisher"},{"url":"https://doi.org/10.1038/npp.2009.39","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19387424","host_type":"repository"}],"fields_of_study":["Attention Deficit Hyperactivity Disorder","Neurotransmitter Receptor Influence on Behavior","Bipolar Disorder and Treatment","Adrenergic Uptake Inhibitors","Atomoxetine Hydrochloride","Attention Deficit Disorder with Hyperactivity","Child","Cohort Studies","Cytochrome P-450 CYP2D6","Double-Blind Method","Female","Haplotypes","Humans","Male","Norepinephrine Plasma Membrane Transport Proteins","Odds Ratio","Polymorphism, Single Nucleotide","Propylamines","Sequence Analysis, DNA","Severity of Illness Index","Treatment Outcome"],"mesh_terms":["Atomoxetine Hydrochloride","Attention Deficit Disorder with Hyperactivity","Child","Double-Blind Method","Female","Haplotypes","Humans","Male","Propylamines","Severity of Illness Index","Cohort Studies","Odds Ratio","Treatment Outcome","Sequence Analysis, DNA","Adrenergic Uptake Inhibitors","Cytochrome P-450 CYP2D6","Polymorphism, Single Nucleotide","Norepinephrine Plasma Membrane Transport Proteins"],"keywords":["Atomoxetine","Norepinephrine transporter","Attention deficit hyperactivity disorder","Methylphenidate","Haplotype","Stimulant","Norepinephrine","Atomoxetine hydrochloride","Psychology","Psychiatry","Gene","Medicine","Neuroscience","Genetics","Dopamine","Biology","Genotype"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T07:29:30.109819Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}